Glucotrack has announced the receipt of St Vincent’s Hospital Melbourne Human Research Ethics Committee’s (HREC) approval for ...

Long-term clinical evaluation represents key advancement following successful first-in-human studyRUTHERFORD, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or ...

On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Ex ...

Net Loss: Net loss for the first quarter of 2025 was $6.8 million compared to a net loss of $2.9 million for the first quarter of 2024. The increase in net loss is attributable primarily to the ...

Learn how emerging technologies are enhancing patient engagement and treatment strategies in everyday practice.

The Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information about Glucotrack's CBGM, ...

With projected growth to US$ 68.5 billion by 2030, the POC diagnostics market presents significant opportunities. Companies ...

Roche Diagnostics plans to produce glucose monitors at the site within three years and prepare for future generations of its ...

Emma Gill had bee been warned about her blood sugar levels being too high before, so she tested out a continuous glucose ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Roche said Monday it plans to invest up to $550 million and add hundreds of jobs over the next five years at its Indianapolis ...